Thomas Linn

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

Rüdiger Göke, H. C. Fehmann, Thomas Linn et al. · Journal of Biological Chemistry · 1993 · 834 citations · Full text

Cross-linking Experiments, Glycobiology, Peptide Science +20

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins

Triantafyllos Chavakis, Angelika Bierhaus, Nadia Al‐Fakhri et al. · The Journal of Experimental Medicine · 2003 · 573 citations · Full text

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

Reinhard G. Bretzel, Ulrike A. Nuber, Wolfgang Landgraf et al. · The Lancet · 2008 · 305 citations

Metabolic Syndrome, Diabetes Management, Basal Insulin Glargine +8

Effect of long-term dietary protein intake on glucose metabolism in humans

Thomas Linn, Budi Santosa, Dietrich Grönemeyer et al. · Diabetologia · 2000 · 245 citations · Full text

Obesity, Nutrition, Metabolic Syndrome +10